Introduction {#S1}
============

Hematopoietic cell transplantation (HCT) is a curative treatment for many hematologic malignancies and nonmalignant disorders, although a variety of complications and late effects may occur.^[@R1]-[@R3]^ Non-graft-versus-host disease (non-GVHD) ocular complications are generally uncommon after HCT, but can cause prolonged morbidity affecting activities of daily living and quality of life. It is important for all health professionals taking care of HCT recipients to have adequate knowledge about ocular complications.

This review summarizes recent updates in non-GVHD ocular complications after HCT in a collaborative effort between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR) and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation (EBMT). We aim to provide an expert review of non-GVHD ocular complications after HCT with evidence-based recommendations for clinical practice and future research. The most frequent ocular complication after allogeneic HCT is ocular GVHD, which is addressed in a companion review.

Structures of the eye are shown in [Figure 1](#F1){ref-type="fig"}. The anterior segment of the eye is formed by the cornea, aqueous humor, iris, ciliary body and crystalline lens. The posterior segment is formed by the vitreous body, retina, choroid and optic nerve.

Methods {#S2}
=======

We searched the Medline (PubMed) database using a broad search strategy to identify studies related to ocular complications after HCT. The primary search was conducted using the terms "hematopoietic transplantation AND (eye OR ocular)," and 552 articles were identified as of March 31, 2018. Relevant articles were also reviewed as needed. Recommendations are organized according to an evidence-based system described previously^[@R4]^ to reflect the strength of recommendations and the quality of evidence supporting them ([Table 1](#T1){ref-type="table"}).

Cataracts {#S3}
=========

Incidence and risk factors {#S4}
--------------------------

Cataracts, defined clinically as progressive opacification of the lens, are one of the most frequent late ocular complications after HCT. The reported incidence of cataracts in HCT survivors varies among studies, ranging from 11% to 100% in adults^[@R5],[@R6]^ and from 4% to 76% in children ([supplementary Table S1](#SD1){ref-type="supplementary-material"}).^[@R7],[@R8]^ This large variability is attributable to heterogeneity in patient populations, conditioning regimens, supportive care, and length of follow-up.

Among patients who undergo allogeneic HCT, total body irradiation (TBI) as part of the conditioning regimen has been identified as a major risk factor for cataract formation. Posterior subcapsular cataracts are the most common subtype associated with exposure to ionizing radiation. The risk of cataracts is much higher after single dose TBI compared to hyper-fractionated TBI.^[@R9]^ A higher dose rate (\>0.04 Gy/min) has also been identified as a risk factor.^[@R10]^ Lens-shielding in patients receiving TBI has been tested, mostly in pediatric patients, and has shown to reduce the incidence and severity of cataracts,^[@R11]^ although controversy exists regarding a potentially increased risk of extramedullary disease relapse in the shielded area. One pediatric study showed that fractionated TBI was assocated with cataracts requiring surgery, while chemotherapy-based conditioning caused less severe cataracts usually not requiring surgery.^[@R12]^

In addition to TBI, prolonged steroid therapy, such as for treatment of GVHD, has been identified as an independent risk factor for cataracts after HCT.^[@R13],[@R14]^ A population-based study showed that even inhaled corticosteroids were associated with the development of posterior subcapsular and nuclear cataracts.^[@R15]^ Survivors of allogeneic HCT are more likely to develop cataracts, when compared with those of autologous HCT.^[@R10]^

Screening, prevention and treatment {#S5}
-----------------------------------

Comprehensive evaluation by ophthalmologists before HCT and then annually after HCT is warranted to diagnose and determine the appropriate timing for surgical intervention of cataracts ([supplementary Table S2](#SD1){ref-type="supplementary-material"}).^[@R16]^ In adults, decreased visual acuity reported by the patients should initiate an eye examination. Pediatric patients require regular follow-up given that they may not complain of visual changes. Cataract prevention with use of fractionated TBI or use of non-TBI conditioning regimens and corticosteroids sparing, when clinically feasible, is the most important for minimizing cataract development.^[@R9],[@R12]^

Surgery is the standard treatment for cataracts. Early diagnosis and appropriate timing for surgery are important in young children, especially those under 7 years old, in order to prevent irreversible amblyopia.^[@R17]^ Cataract surgery is usually indicated for those with bilateral cataracts and best corrected visual acuity of 20/40 or worse, although the visual threshold for performing surgery should be tailored according to the needs of the patient. In both adult and pediatric patients, cataracts may present with dry eye and other manifestations of ocular GVHD. The concurrent ocular surface problems and postoperative complications should be controlled to obtain good surgical outcomes in these patients.^[@R18]^

Ocular infections {#S6}
=================

Ocular infections can be severe after HCT. The types of infectious organisms, involved ocular structures, symptoms and diagnostic tests are summarized in [Table 2](#T2){ref-type="table"}.

Incidence and risk factors {#S7}
--------------------------

The incidence of ocular infections has decreased over time with advances in prophylaxis, screening guidelines and effective medications.^[@R19],[@R20]^ In a large series of 620 patients undergoing allogeneic HCT, 18 (3%) had serious ocular infections due to Gram-positive and negative bacteria (1.6%), fungi (0.16%), and virus (0.8%).^[@R21]^ *Candida* and *Aspergillus* species are the most frequently isolated organisms in fungal keratitis and endophthalmitis.^[@R22]^ The most common ocular protozoan infection is *Toxoplasma gondii,* although ocular toxoplasmosis is rare (0.3-0.5% of autologous and allogeneic HCT recipients).^[@R23],[@R24]^ Viruses that cause ocular infection after HCT include cytomegalovirus (CMV),^[@R25]-[@R28]^ herpes simplex virus (HSV),^[@R29]^ varicella zoster virus (VZV),^[@R30],[@R31]^ and adenovirus (ADV).^[@R32]^ The most common virus that affects the eyes is CMV, with the incidence of retinitis ranging from \<1% to 5% in all HCT recipients, and from 5% to 23% in patients with CMV viremia.^[@R25]-[@R28]^ Ocular infections by HSV, VZV and ADV are rare.^[@R29]-[@R31]^ In one study, ocular infection accounted for 2% of all VZV infections.^[@R30]^

Since ocular infections are uncommon, risk factors are often extrapolated from those for infections at other sites and include pre-HCT latent infections and post-HCT neutropenia, impaired cellular and humoral immunity and development of GVHD ([Figure 2](#F2){ref-type="fig"}).^[@R19],[@R21]^ Patients with neutropenia or humoral deficiency are susceptible to developing bacterial infections, including corneal ulcers and periorbital cellulitis.^[@R21]^ Risk factors for ocular fungal infection include fungemia and immunosuppression.^[@R33]^ Risk factors for ocular toxoplasmosis include toxoplasma infection before HCT and impaired cellular immunity.^[@R23]^ Risk factors for viral infections include positive serostatus before HCT, history of viremia before HCT, low lymphocyte counts, chronic GVHD, HLA mismatching, and unrelated donor.^[@R25]-[@R27],[@R30]^ Candidates for HCT should undergo serologic testing for latent viral infections and toxoplasmosis.^[@R19],[@R20]^

Screening, prevention and treatment {#S8}
-----------------------------------

Eye examination should be performed before HCT and at any time when patients have ocular symptoms after HCT. Early detection and prompt treatment are required to prevent visual loss. Prevention and treatment of ocular infections is similar to that of other systemic infections except where ocular penetration of the therapeutic agent is poor.

Bacterial infections are treated with systemic antibiotics based on culture and sensitivity results. Topical antibiotics are also used for bacterial keratitis.^[@R34]^ Systemic antifungal therapy is considered for patients with ocular fungal infection depending on the causative pathogen. Intravitreal administration can be performed with most antifungal agents, including amphotericin B, echinocandins and azoles, as penetration into eyes may not be sufficient with intravenous administration.^[@R35]^ To treat fungal keratitis, antifungal agents such as voriconazole can be used topically.^[@R36]^ There are no randomized trials comparing the efficacy of different prophylactic agents to prevent toxoplasmosis after HCT, although observational studies have demonstrated efficacy of trimethoprim-sulfamethoxazole from engraftment until immunosuppressive therapy is discontinued.^[@R37]^ Treatment of active toxoplasmosis consists of antimicrobial agents such as trimethoprim-sulfamethoxazole, pyrimethamine/sulfadiazine, clindamycin, atovaquone, or azithromycin.^[@R38]^

Systemic therapy (e.g. ganciclovir and foscarnet) should be used for treatment of CMV ocular diseases.^[@R28]^ When patients do not respond sufficiently to systemic therapy, intravitreous therapy is considered.^[@R28]^ Third-party donor-derived CMV pp65-specific T-cells have resulted in resolution of refractory CMV retinitis.^[@R39]^ Prophylactic acyclovir has reduced the risk of HSV infection.^[@R40]^ A combination of systemic therapy and topical therapies is recommended for treatment of HSV ocular infection. Intravenous cidofovir is recommended for treatment of ADV infection.^[@R41]^

Ocular involvement by malignancy {#S9}
================================

Incidence and diagnosis {#S10}
-----------------------

There is very limited information regarding ocular manifestations of malignancy after HCT. The incidence of ocular involvement by malignancy is rare. Relapsed disease after HCT may involve eyes, either *de novo* or in association with central nervous system or systemic relapse.^[@R42],[@R43]^

Clinical presentations of intraocular neoplasms after HCT can include the anterior and posterior segments and orbital manifestations, amongst others. Despite the infrequent incidence of *de novo* or recurrent ocular neoplasms, a high index of suspicion necessitates proper clinical assessment and evaluation by an experienced ophthalmologist.^[@R44]^ Computed tomography or magnetic resonance imaging may be helpful. Cytology, immunohistochemistry, flow cytometry, cytogenetics and molecular studies on aspirated fluid or tissue biopsy are necessary for definitive diagnosis.^[@R44]-[@R46]^

Screening, prevention and treatment {#S11}
-----------------------------------

No evidence is available for screening and prevention of malignancies with ocular involvement. As a general recommendation, ocular evaluation may be necessary in patients with relapsed primary disease and ocular symptoms, in those with previous ocular involvement, and in those with new malignancy involving the central nervous system. Treatment approaches are extrapolated from literature on treatment of intraocular neoplasms in general and are not validated in HCT settings. These include intravitreal chemotherapy, radiation, photodynamic laser therapy, and disease-specific interventions based on site and histology of neoplasm.^[@R47]-[@R49]^

Ischemic microvascular retinopathy {#S12}
==================================

Incidence and risk factors {#S13}
--------------------------

Ischemic microvascular retinopathy (IMR) after HCT is a complication of the posterior segment that was first described in 1983.^[@R50]^ IMR presents with retinal cotton-wool patches, vitreous hemorrhage and optic disc edema. The clinical presentation varies from asymptomatic to sight-threatening forms. Symptomatic patients often complain of blurred vision or color vision abnormality which can occur abruptly, gradually or progressively. One or both eyes can be affected.

There are at least 8 cohort studies examining complications of the posterior segment after HCT ([supplementary Table S3](#SD1){ref-type="supplementary-material"}).^[@R21],[@R22],[@R51]-[@R56]^ IMR has been reported after both autologous and allogeneic HCT, and the incidence of IMR ranges from 0% to 10%,^[@R21],[@R22],[@R51]-[@R56]^ although the incidence is likely to be underestimated due to the asymptomatic presentation in many patients. IMR usually occurs within 6 months of allogeneic HCT,^[@R52]^ although atypically late onset around 50 months after allogeneic HCT has been described in 4 patients.^[@R54]^ Potential risk factors for IMR include TBI conditioning,^[@R22],[@R52],[@R54]^ cyclosporine prophylaxis,^[@R22],[@R52]^ and conditioning regimens including busulfan or carmustine.^[@R53],[@R54]^

Pathogenesis {#S14}
------------

Although the pathogenesis of HCT-associated IMR has not yet been elucidated, multifactorial processes are likely to cause capillary damage in the ocular fundus. IMR after HCT is morphologically similar to fundus changes associated with malignant hypertension in the general population,^[@R57]^ but most HCT patients with IMR do not have malignant hypertension, suggesting a different pathogenesis. Although radiation has been associated with vascular retinopathy,^[@R58]^ IMR also occurs among adult patients who have had autologous HCT using non-TBI conditioning regimens.^[@R53]^ In an experimental rat model using retinal imaging, the combination of cyclosporine and dexamethasone led to progressive degenerative changes of the fundus with histologic thinning of the outer nuclear layer of the retina, suggesting that calcineurin inhibitors may contribute to ocular vascular endothelial injury.^[@R59]^

Screening, prevention and treatment {#S15}
-----------------------------------

Data are lacking for the management of IMR after HCT. Based on the potential risk factors, it is important to avoid radiation to ocular areas, to monitor levels of calcineurin inhibitors, and to treat cardiovascular risk factors such as hypertension, diabetes, and hyperlipidemia. Importantly, spontaneous regression is frequent and permanent loss of visual acuity is rare. Withdrawal or reduction of immunosuppression can lead to resolution of the retinal lesions in many cases,^[@R60]^ although proliferative retinopathy may have a poor visual prognosis.^[@R61]^

Future research should focus on the biology of IMR and identification of risk factors. Novel findings in retinopathy due to diabetes and sickle cell disease are worth investigating in HCT patients with IMR. For example, new sensitive technologies of ultra-wide field fluorescein angiography, spectral-domain optical coherence tomography and optical coherence tomography angiography may help diagnosis.^[@R62],[@R63]^ Vascular endothelial growth factor (VEGF) may serve as a diagnostic biomarker and a treatment target, since tissue ischemia increases VEGF that can promote abnormal neovascularization.^[@R64]^

Other ocular complications {#S16}
==========================

Glaucoma {#S17}
--------

Glaucoma was diagnosed in 1.7% of HCT survivors, but this frequency was similar to 1.9% in their siblings.^[@R65]^ In a study of 218 patients with chronic GVHD, 33 (15%) had increased intraocular pressure, 8 (3.6%) had suspicion of glaucoma, and 1 (0.4%) had glaucoma.^[@R66]^ Classically, glaucoma is known as a late complication of irradiation used in conditioning regimens, with a median interval of 22 months to onset of glaucoma.^[@R67]^ Long-term use of systemic corticosteroids for chronic GVHD can elevate intraocular pressure in susceptible patients.^[@R66],[@R68],[@R69]^ The risk of early intraocular pressure rise and amount of elevation are greater in children than adults.^[@R70]^ Intraocular pressure may be elevated even after topical steroid use such as eye drops, ointment and inhalation. Other factors associated with open angle glaucoma are infectious keratitis and eye rubbing.^[@R68]^ No correlation has been demonstrated between stem cell source and glaucoma.^[@R21]^

Patients who are receiving systemic or topical steroids should have periodic monitoring of intraocular pressure. A rise in intraocular pressure is often transient and resolves within 4 weeks of tapering or cessation of systemic steroid therapy.^[@R66]^ If steroid use exceeds 18 months, the intraocular pressure may be permanently elevated. First-line treatment of glaucoma is topical aqueous humor suppressants, including beta-blockers, alpha 2 agonists, or carbonic anhydrase inhibitors.^[@R71],[@R72]^ For the 1-5% of patients with intractable glaucoma not adequately responsive to eye drop treatment, glaucoma surgery with trabeculectomy or other technique may be necessary to prevent vision loss.^[@R73]^ Laser trabeculoplasty has shown efficacy in small retrospective studies.^[@R74]^

Central retinal vein occlusion (CRVO) {#S18}
-------------------------------------

CRVO is a vision-threatening retinal vascular disease, with an incidence of 0.2%-0.4% in the general population.^[@R75]^ The pathophysiology of CRVO is not yet fully understood, but systemic diseases including hypertension, hyperlipidemia and diabetes mellitus, hypercoagulability and hyperviscosity may be associated with its pathophysiology. There are several reports of CRVO in patients with hematologic malignancies, but only two cases of CRVO have been reported at 2 and 5 months after HCT.^[@R76]^

The central retinal vein is compressed in patients with CRVO by the adjacent central retinal artery at the lamina cribrosa, leading to increased venous and capillary pressures, endothelial damage, permeability changes, and extravasation of blood and serous fluid in the retina. Capillary perfusion is reduced due to increased interstitial pressures, causing tissue ischemia. Interleukin-6 and VEGF are secreted in response to the ischemia, which promotes retinal edema, neovascularization and other complications including vitreous hemorrhage, tractional retinal detachment, iris neovascularization and neovascular glaucoma.^[@R77]^

Intravitreal injections of anti-VEGF agents are the first-line treatment for symptomatic macular edema due to CRVO, and have shown significant reduction in central retinal thickness from macular edema, significant improvement in best corrected visual acuity and a delay in development of neovascular complications in randomized studies.^[@R78],[@R79]^ Intravitreal steroid injections also have improved macular edema after CRVO in a randomized study.^[@R80]^ A retrospective study showed that macular grid and panretinal laser photocoagulation are also effective for CRVO,^[@R81]^ and these treatments are considered as second line or in cases with extensively ischemic retina.

Retinal hemorrhage and retinal detachment {#S19}
-----------------------------------------

Retinal hemorrhage and detachment usually occur as a consequence of other pathologies such as CMV retinitis and neovascularization due to ischemic retinopathy. A retrospective study of 635 patients who had allogeneic HCT showed that the most common posterior segment complication after allogeneic HCT was retinal hemorrhage (3.2%).^[@R76]^ Standard treatments include platelet transfusion to maintain the platelet count over 50,000/μl and correction of coagulopathy.

Retinal detachment is a rare posterior segment complication and accounts for \<1% of ocular complications after HCT.^[@R22],[@R76]^ It can be seen in chronic GVHD, CMV retinitis, and rarely in acute GVHD. Most of the cases manifest as rhegmatogenous retinal detachment,^[@R76],[@R82]^ but 2 cases of vision-threatening exudative bullous retinal detachment have been reported in the literature.^[@R83]^ Tractional retinal detachment due to proliferative retinopathy has also been reported after HCT.^[@R84]^ In one study, retinal detachment occurred in 13% patients with CMV retinitis, and the visual prognosis was often poor.^[@R76]^ Treatment depends on underlying disease and includes laser photocoagulation, cryotherapy, and various surgical techniques.

Medications with ocular toxicities {#S20}
==================================

A variety of medications can cause ocular toxicities after HCT ([Table 3](#T3){ref-type="table"}). The most commonly reported ocular toxicity of anti-cancer drugs is keratoconjunctivitis. Systemic corticosteroids accelerate cataract formation^[@R13],[@R14],[@R85]^ and glaucoma development.^[@R66]^ Topical corticosteroids are commonly used for treatment of ocular GVHD, but their long-term use is associated with elevated intraocular pressure, decreased epithelial healing, infection and cataracts.^[@R18]^ High-potency steroid eye drops should be avoided, and intraocular pressure should be monitored in patients who continue steroid eye drops for more than 2 weeks.^[@R66]^ Topical use of tacrolimus and cyclosporine for treatment of ocular GVHD can cause conjunctival injection, burning and stinging sensation, which may be controlled with lubricating eye drops.^[@R86]-[@R88]^ Voriconazole can cause blurred vision, changes in visual acuity and color perception, photophobia and visual hallucinations.^[@R89]^ Other medications such as antihistamines^[@R90]^ (e.g., diphenhydramine, loratadine) and anticholinergics^[@R91]^ (e.g., sedatives, sleep aids, cold preparations, antidiarrheal and nasal decongestants) can inhibit lacrimal glandular secretions and cause dry eyes. Scopolamine patches used as antiemetic after high-dose chemotherapy can lead to anisocoria or mydriasis if the eye is contaminated with scopolamine.^[@R92]^ Selective serotonin reuptake inhibitors can result in reduced accommodation.^[@R93]^ Antipsychotics including phenothiazines such as haloperidol, chlorpromazine and thioridazine can cause mydriasis, cycloplegia,^[@R93]^ and pigmentation of conjunctiva, cornea, eyelids and retina with their long-term use.^[@R94]^ Sildenafil used for erectile dysfunction after HCT can cause a blue tinge to vision or an increased brightness of lights.^[@R95]^ Topical nonsteroidal anti-inflammatory eye drops can cause stromal necrosis in dry eyes, and should be avoided in patients with ocular GVHD.^[@R96]^

Summary and future recommendations {#S21}
==================================

The incidence, risk factors, screening and prevention recommendations for non-GVHD ocular complications after HCT are summarized in [Table 4](#T4){ref-type="table"}. Treatment recommendations are summarized in [Table 5](#T5){ref-type="table"}. Although non-GVHD ocular complications after HCT are rare, baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up ocular evaluations should be considered according to clinical findings and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT, particularly in high-risk patients. There is significant overlap in the clinical presentation between infectious and non-infectious ocular complications and better diagnostic techniques need to be developed. There remains a paucity of data on the long-term visual outcomes, particularly in pediatric patients, as most studies have short follow up of less than 2 years. Better data collection is necessary to address these remaining questions. Both transplant physicians and ophthalmologists should be knowledgeable about non-GVHD ocular complications and provide a comprehensive collaborative team care.
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###### 

Evidence-based rating system used in this review

  Category Definition                                  
  ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Strength of the Recommendation:                      
   A                                                   Should always be offered.
   B                                                   Should generally be offered.
   C                                                   Evidence for efficacy is insufficient to support a recommendation for or against, or evidence for efficacy might not outweigh adverse consequences, or cost of the approach. Optional.
   D                                                   Moderate evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should generally not be offered.
   E                                                   Good evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should never be offered.
  Quality of Evidence Supporting the Recommendation:   
   I                                                   Evidence from at least one properly randomized, controlled trial.
   II                                                  Evidence for at least one well-designed clinical trial without randomization, from cohort or case-controlled analytic studies (preferable from more than one center) or from multiple time-series or dramatic results from uncontrolled experiments.
   III                                                 Evidence from opinions of respected authorities based on clinical experience, descriptive.

###### 

Involved structures, symptoms and diagnostic tests of ocular infections following HCT

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Organism                                                               Involved structures                      Symptoms and clinical findings                                                                      Diagnostic tests
  ---------------------------------------------------------------------- ---------------------------------------- --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bacteria^[@R21]^\                                                      Lids, conjunctiva, cornea, intraocular   Pain or irritation, erythema, discharge, photophobia, impaired vision                               Conjunctival culture, culture of corneal scrapings or vitreal fluid
  * Staphylococci, Haemophilus, Streptococci, Pseudomonas, and others*                                                                                                                                                

  Fungi^[@R21]^                                                          Cornea, intraocular                      Pain, erythema, photophobia, excessive tearing or discharge, blurred vision, vision loss            Corneal infiltrates with feathery edges, culture of corneal scrapings or vitreal fluid

  Toxoplasma^[@R23],[@R24]^                                              Retina                                   Pain, photophobia, scotoma, blurred vision, vision loss                                             Raised, yellow/white, cottony retinal lesions in a non-vascular distribution and vitreal inflammation, serum PCR or serology, PCR of aqueous humor, vitreal fluid and tissue

  Virus                                                                                                                                                                                                               

   Cytomegalovirus^[@R25]-[@R28]^                                        Retina                                   May be asymptomatic early, visual loss, floaters, progressive visual loss                           Dilated pupil examination showing cream-colored lesions with hemorrhage and perivascular cuffing of retinal vessels, PCR of vitreous fluid

   Herpes simplex virus^[@R29]^\                                         Conjunctiva, cornea                      May be asymptomatic, periorbital pain or rash, conjunctival erythema, blurred vision, vision loss   Swelling and cloudiness of cornea on ophthalmologic exam, PCR, DFA from base of skin lesion scrapings, viral culture
   Varicella zoster virus^[@R30],[@R31]^                                                                                                                                                                              

   Adenovirus^[@R32],[@R41],[@R97]^                                      Conjunctiva, cornea                      Erythema, chemosis, discharge                                                                       Culture, PCR
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PCR, polymerase chain reaction; DFA, direct fluorescent assay.

###### 

Medications with ocular toxicities

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug                                                                                           Ocular toxicity                                                                                                                                                                     Frequency                                       Management and prevention\                                                                                  Strength
                                                                                                                                                                                                                                                                                                                                     recommendation                                                                                              
  ---------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ----------------------------------------------------------------------------------------------------------- ----------
  **Cytosine arabinoside**                                                                       Keratoconjunctivitis^[@R98]^                                                                                                                                                        Common                                          Prophylactic glucocorticoid eye drops,^[@R98]^ 2-deoxycytidine eye drops applied prior to therapy^[@R98]^   A-II

                                                                                                 Ocular pain, tearing, foreign body sensation, photophobia, epiphora, blurred vision with evidence of bilateral conjunctival hyperemia and fine corneal punctate opacities^[@R98]^   Occasional                                      Eye washing with physiologic saline, 0.1% sodium betamethasone eye drops applied prior to therapy           B-III

  **Imatinib**                                                                                   Peri-orbital edema, sometimes leading to visual obstruction^[@R99]^                                                                                                                 Common                                          Warm compress                                                                                               A-III

  **Corticosteroids (systemic)**                                                                 Cataracts,^[@R13],[@R14],[@R85]^ increased IOP, glaucoma^[@R66],[@R68],[@R69]^                                                                                                      Common                                          Limit use                                                                                                   A-III

                                                                                                                                                                                                                                                                                                                                     Screening for cataracts and glaucoma                                                                        C-III

  **Corticosteroids (topical)**                                                                  Increased IOP, glaucomatous optic atrophy, visual field defects, cataracts, infectious keratitis                                                                                    Occasional to rare                              Monitor IOP within 1 month of initiating treatment, restrict extended use of high potency steroids          A-III

                                                                                                                                                                                                                                                                                                                                     Regular screening for cataracts, surgery as needed^[@R18]^                                                  B-III

                                                                                                                                                                                                                                                                                                                                     Discontinue steroids,^[@R66]^ topical aqueous humor suppressants,^[@R71],[@R72]^ trabeculectomy^[@R73]^     A-I

  **Cyclosporine (systemic)**                                                                    Microvascular retinopathy^[@R60]^                                                                                                                                                   Rare                                            Improve with drug discontinuation^[@R60]^                                                                   A-II

  **Cyclosporine (topical)**                                                                     Redness, stinging, burning                                                                                                                                                          Occasional                                      Lubricating drops,^[@R88]^ chill bottle^[@R87]^ before instilling cyclosporine                              A-II

  **Tacrolimus (topical)**                                                                       Burning sensation                                                                                                                                                                   Common                                          Symptoms typically improve in 1 month after drug discontinuation.^[@R86]^                                   A-II

  **Phenothiazines** (chlorpromazine, thioridazine)                                              Abnormal pigmentation of the eyelids, interpalpebral conjunctiva and cornea with long-term use^[@R94]^                                                                              Common                                          Improve with drug discontinuation                                                                           B-III

                                                                                                 Decreased accommodation and deposits in the lens                                                                                                                                    Common                                          Topical cholinergic agent (pilocarpine)                                                                     B-III

  **Tricyclic antidepressants** (amitriptyline)                                                  Mydriasis, cycloplegia, blurred vision, presbyopia, mild and transient visual disturbances^[@R93]^                                                                                  Common                                          Improve with time as tolerance develops.^[@R93]^ Topical cholinergic agents (bethanechol or pilocarpine)    B-II

                                                                                                 Decreased lacrimation, dry eyes, glaucoma attacks (anticholinergic)                                                                                                                 Rare to common                                  Artificial tears, avoid in patients with narrow angles^[@R93]^                                              B-II

  **Selective serotonin reuptake inhibitors** (sertraline, paroxetine, fluoxetine, citalopram)   Mydriasis, reduced accommodation, increased IOP, glaucoma,^[@R93]^ blurred vision                                                                                                   Common                                          Improve with drug discontinuation                                                                           B-III

  **Antihistamines** (chlorpheniramine, meclizine, promethazine, diphenhydramine)                Mydriasis (anticholinergic)^[@R90]^, dry eyes, decreased accommodation                                                                                                              Common                                          Transient, reversible                                                                                       B-III

  Angle closure glaucoma (anticholinergic)                                                       Rare                                                                                                                                                                                Avoid in patients with angle closure glaucoma   B-III                                                                                                       

  **Scopolamine patch**                                                                          Anisocoria, mydriasis, dry eyes^[@R92]^                                                                                                                                             Common                                          Avoid rubbing eyes with fingers after application of the patch^[@R92]^                                      A-II

  **Voriconazole**                                                                               Blurred vision, changes in visual acuity, color perception, photophobia, visual hallucinations^[@R89]^                                                                              Common                                          Consider alternative drugs                                                                                  A-III

  **Erectile dysfunction drugs** (e.g., sildenafil)                                              Blue vision^[@R95]^                                                                                                                                                                 Common                                          Improve with drug discontinuation                                                                           B-II

  **Non-steroidal anti-inflammatory drugs (topical)**                                            Redness, stinging, corneal epithelial toxicity, stromal necrosis (corneal melts) especially in dry eyes                                                                             Occasional                                      Limit use for dry eye or GVHD, drug discontinuation^[@R96]^                                                 B-II
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IOP, intraocular pressure; GVHD, graft-versus-host disease.

###### 

Incidence, risk factor, screening and prevention recommendations of non-GVHD ocular complications after HCT

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Complication                                                Incidence                                                                                   Risk factor                                                                                                                                                                                                                                         Prevention and screening recommendation\
                                                                                                                                                                                                                                                                                                                                                                                                              (strength)
  ----------------------------------------------------------- ------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cataracts                                                   11%-100% in adults,^[@R5],[@R6]^ 4%-76% in children^[@R7],[@R8]^                            TBI (particularly single dose or dose rate\>0.04 Gy/min),^[@R9],[@R10]^ corticosteroids,^[@R13]-[@R15]^ allogeneic HCT^[@R10]^                                                                                                                      Hyper-fractionated TBI instead of single-dose TBI^[@R9]^ (A-I), non-TBI conditioning^[@R12]^ (B-II), lens shielding^[@R11]^ (C-II)

  Bacterial infection                                         \<2%^[@R21]^                                                                                Neutropenia,^[@R21]^ impaired humoral immunity^[@R21]^                                                                                                                                                                                              By clinical presentation (A-II)

  Fungal infection                                            \<2%^[@R21],[@R22]^                                                                         Fungemia^[@R33]^, immunosuppression^[@R33]^                                                                                                                                                                                                         By clinical presentation or fungemia^[@R33]^ (A-III)

  Toxoplasma infection                                        0.3-0.5%^[@R23],[@R24]^                                                                     Pre-HCT infection,^[@R23]^ impaired cellular immunity^[@R23]^                                                                                                                                                                                       Pre-HCT screening examination for retina scar and serologic testing^[@R37]^ (B-III), by clinical presentation

  Viral infection                                                                                                                                                                                                                                                                                                                                                                                             

   Cytomegalovirus (CMV)                                      Retinitis \<1%-5% in all HCT patients, 5%-23% in patients with CMV viremia^[@R25]-[@R28]^   Positive serostatus,^[@R25]^ viremia pre-HCT,^[@R27]^ reactivation by day+100,^[@R25]^ high peak DNA levels,^[@R26]^ delayed lymphocyte engraftment,^[@R25]^ chronic GVHD,^[@R25],[@R27]^ HLA mismatching,^[@R26],[@R27]^ unrelated donor^[@R26]^   Screening fundiscopic examination in patients at risk every 6-8 weeks (B-III)

   Herpes simplex virus (HSV), Varicella zoster virus (VZV)   Rare,^[@R29],[@R31]^ 2% of VZV infection^[@R30]^                                            Extensive chronic GVHD^[@R30]^                                                                                                                                                                                                                      By clinical presentation (A-III), prophylactic acyclovir^[@R40]^ (A-I)

   Adenovirus                                                 Rare                                                                                        No data                                                                                                                                                                                                                                             PCR surveillance for systemic reactivation in high risk patients (B-III)

  Involvement with malignancy                                 Rare                                                                                        No data                                                                                                                                                                                                                                             Evaluation of ocular involvement in patients with relapsed primary disease and ocular symptoms^[@R42],[@R43]^ (C-III), and in asymptomatic high-risk patients (previous ocular involvement, new malignancy involving central nervous system)^[@R44]^ (C-III)

  Ischemic microvascular retinopathy                          0-10%^[@R21],[@R22],[@R51]-[@R56]^                                                          TBI, ^[@R22],[@R52],[@R54]^ cyclosporine,^[@R22],[@R52]^ conditioning regimens including busulfan or carmustine^[@R53],[@R54]^                                                                                                                      Avoid radiation to ocular areas, monitor levels of calcineurin inhibitors (B-III)

  Glaucoma                                                    0.4-1.7%^[@R65],[@R66]^                                                                     Irradiation,^[@R67]^ topical or systemic corticosteroids^[@R66],[@R68],[@R69]^                                                                                                                                                                      Monitor intraocular pressure in patients with risk factors (A-II)

  Central retinal vein occlusion                              Rare                                                                                        Hypertension, hyperlipidemia, diabetes mellitus, hypercoagulability, hyperviscosity                                                                                                                                                                 Funduscopic testing if visual acuity impairment (A-III)

  Retinal hemorrhage                                          3.2%^[@R76]^                                                                                Cytopenia, particularly thrombocytopenia                                                                                                                                                                                                            Funduscopic testing if visual acuity impairment (A-III)

  Retinal detachment                                          \<1%.^[@R22],[@R76]^                                                                        CMV retinitis^[@R76]^                                                                                                                                                                                                                               Funduscopic testing if visual acuity impairment (A-III)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TBI, total body irradiation; HCT, hematopoietic cell transplantation; GVHD, graft-versus-host disease.

###### 

Treatment recommendations of non-GVHD ocular complications after HCT

  Complication                         Treatment recommendation                                                                                                                                          Strength
  ------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------
  Cataracts                            Surgery^[@R17]^                                                                                                                                                   A-II
  Bacterial infection                  Antibiotic eye drops,^[@R34]^ oral or intravenous antibiotic agents, intravitreal injections                                                                      A-I
  Fungal infection                     Antifungal eye drops,^[@R36]^ oral or intravenous antifungal agents, intravitreal injections^[@R35]^                                                              A-I
  Toxoplasma infection                 Trimethoprim-sulfamethoxazole-pyrimethamine, clindamycin, atovaquone, azithromycin^[@R38]^                                                                        A-I
  Viral infection                                                                                                                                                                                        
   Cytomegalovirus                     Intravenous ganciclovir, oral valganciclovir, intravenous foscarnet^[@R28]^                                                                                       A-II
                                       Intravitreal ganciclovir or foscarnet for resistant infections^[@R28]^                                                                                            B-II
                                       Virus-specific T-cell infusion^[@R39]^                                                                                                                            C-II
   Herpes simplex virus                Oral acyclovir/valacyclovir/famciclovir, intravenous acyclovir                                                                                                    A-II
   Varicella zoster virus              Oral acyclovir/valacyclovir/famciclovir, intravenous acyclovir for opthalmicus                                                                                    A-II
   Adenovirus                          Decrease immunosuppression, intravenous cidofovir^[@R41]^                                                                                                         A-II
  Involvement with malignancy          Intravitreal chemotherapy, radiation therapy, photodynamic laser therapy, disease-specific interventions based on site and histology of neoplasm^[@R47]-[@R49]^   C-III
  Ischemic microvascular retinopathy   Reduction or withdrawal of calcineurin inhibitors,^[@R60]^ treatment for hypertension, GVHD and transplant-associated microangiopathy                             B-III
  Glaucoma                             Discontinue steroids,^[@R66]^ topical aqueous humor suppressants,^[@R71],[@R72]^ trabeculectomy^[@R73]^                                                           A-I
  Central retinal vein occlusion       Intravitreal anti-VEGF injections^[@R78],[@R79]^                                                                                                                  A-I
                                       Intravitreal glucocorticoids^[@R80]^                                                                                                                              B-I
                                       Macular grid and panretinal laser photocoagulation^[@R81]^                                                                                                        C-II
  Retinal hemorrhage                   Maintain the platelet count over 50,000/μl                                                                                                                        B-III
  Retinal detachment                   Photocoagulation, cryotherapy and surgical techniques                                                                                                             B-III

VEGF, vascular endothelial growth factor.
